1. No category

INFORMATION
Scientific Organizer
Prof. Dr. med. Nisar P. Malek
Ärztlicher Direktor
Medizinische Universitätsklinik
Abteilung Innere Medizin I
Otfried-Müller-Str. 10
72076 Tübingen
Fon: +49 (0)7071 298 272-1
Fax: +49 (0)7071 292 095
Email: Nisar.Malek@med.uni-tuebingen.de
VENUE & NOTES
Hotel Pullman Berlin Schweizerhof
Budapester Straße 25
10787 Berlin
Germany
Angelika Gohde
Sekretariat Prof. Malek
Medizinische Universitätsklinik Tübingen
Abteilung Innere Medizin I
Otfried-Müller-Str. 10
72076 Tübingen
Fon: +49 (0)7071 298 272-2
Fax: +49 (0)7071 292 095
Email: Angelika.Gohde@med.uni-tuebingen.de
Authorized Congress Agency
eration
In Coop
with:
Certification:
6 CME Points
5 AIO Points
ravel
rged. T
a
h
c
e
b
ot
arate
. A sep he
e will n
d
e
f
e
s
n
r
io
u
t
in t
ipa
imb
A partic will not be re to participate
s
y
e
r
s
a
expen
necess s”.
ation is
ngres
registr
erbstko
H
O
I
A
„11.
e visit:
n pleas
io
t
a
m
r
o
ss.de
ther inf
For fur herbstkongre
iowww.a
n:
Attentio
4
ber 201
0th Octo
ocx)
doc or .d
(.
a
le
tr
fi
s
b
d
r
A
o
ct as a w
r abstra roup.com.
u
o
y
d
n
g
se
ciPlease
rner@m
lika.fah
e
g
n
a
to
line: 1
ct Dead
ACADEMIC DRUG DEVELOPMENT IN ONCOLOGY
- TRANSLATING BASIC SCIENCE RESEARCH
INTO INNOVATIVE TREATMENTS
12th NOVEMBER 2014 IN BERLIN
Congress Office
MCI Deutschland GmbH | München Office
Angelika Fahrner
Neumarkter Str. 21, 81673 München
Fon: +49 (0)89 549 096-74
Fax: +49 (0)89 549 096-75
Email: angelika.fahrner@mci-group.com
6th AIO - SYMPOSIUM
Dear colleagues,
on November 12th we will be holding our 6th AIO-Symposium
on „Academic Drug Development in Oncology“. As in the
previous years we will showcase a number of interesting and
important advances in academic drug development. This year
we will address three clinically important areas.
The use of modified viruses to treat cancer is a longstanding
hope in the field of oncology. Throughout the recent years
this innovative approach has seen a number of different
developments which have been translated into clinical trials.
We will introduce these new types of oncolytic therapies and
describe the way forward towards individualized treatment in
virus based oncologic therapies.
Every cell depends on a set of core mechanisms which helps
it to withstand stress, regulate its metabolism and control
aging. Interestingly such mechanisms can also be exploited
to device innovative new treatments which might help to
overcome resistance and result in longstanding responses. We
will therefore introduce new targets in metabolism, ageing and
autophagy and discuss their potential use in oncology.
The organisation and funding of academic drug development
is an important pillar in the generation of new treatments. It
involves universities, research institutes outside academia
and also a close collaboration with industry. In the last part
of the symposium we will present these different approaches
and also try to understand how they can interact in the most
productive way.
PROGRAM
CHAIRS & SPEAKERS
09.00
Welcome
Dr. Matthias Gottwald,
Bayer HealthCare, Leverkusen
Session 1:
Using viruses to treat cancer
(Chair: Ulrich M. Lauer, Tübingen)
09.10-09.35
09.45-10.10
10.20-10.50
Coffee Break
10.50-11.15
11.25-11.35
Virotherapeutic Vectors in Current Clinical
Evaluation
Ulrich M. Lauer, Tübingen
Short talk 1
11.45-13.00
Lunch
Session 2:
Targeting cellular homeostasis
(Chair: Ingrid Hoffmann, Heidelberg)
13.00-13.25
14.45-15.10
DNA damage induced differentiation
suppresses mutation accumulation in aging
stem cells and carcinogenesis
Lenhard Rudolph, Jena
ATG5: a multitasking molecule
Hans-Uwe Simon, Bern
The Role of Glucose and Lipid Metabolism in
Growth and Survival of Cancer Cells
Almut Schulze, Würzburg
Short talk 2
15.15-15.45
Coffee break
Session 3:
Academic drug development
(Chair: Nisar P. Malek, Tübingen)
15.45-16.10
Natural >Synthetic >Targeted Anticancer
Agents
Ludger Wessjohann, Halle
IMI1 and 2, new ways to optimize R&D in
drug development
Matthias Gottwald, Leverkusen
Concluding remarks
Nisar Malek, Tübingen
13.35-14.00
14.10-14.35
As in our previous years we are also inviting young
investigators to submit abstracts which will be chosen for
short presentations within this meeting. We hope that as in our
previous symposiums we will be able to connect different areas
of drug development to help bridge the gap between basic
research and clinical application.
I am very happy to invite you to join us in Berlin for this
transdisciplinary symposium.
With best regards
Prof. Dr. Nisar P. Malek
for the AIO-Arbeitsgruppe Wirkstoffentwicklung
frühe Phase I/II-Studien
Principles of Tumor Targeted Virotherapeutics
Michael Mühlebach, Langen
Engineering Measles Virus for Cancer Therapy
Guy Ungerechts, Heidelberg
16.20-16.55
17.05
Prof. Dr. med. Volker Heinemann
Klinikum der Universität München - Großhadern, München
Prof. Dr. Ingrid Hoffmann
Deutsches Krebsforschungszentrum, Heidelberg
Prof. Dr. med. Ulrich M. Lauer
Universitätsklinikum Tübingen, Tübingen
Prof. Dr. med. Nisar P. Malek
Universitätsklinikum Tübingen, Tübingen
Dr. Michael Mühlebach
Paul-Ehrlich-Institut, Langen
Prof. Dr. K. Lenhard Rudolph
Leibniz-Institut für Altersforschung
- Fritz-Lipmann-Institut e.V. (FLI), Jena
Prof. Dr. Almut Schulze
Julius-Maximilians-Universität Würzburg, Würzburg
Prof. Dr. Dr. Hans-Uwe Simon
University of Bern, Bern
PD Dr. med. Dr. rer. nat. Guy Ungerechts
Nationales Centrum für Tumorerkrankungen (NCT)
Heidelberg, Heidelberg
Prof. Dr. Ludger Wessjohann
Leibniz-Institut für Pflanzenbiochemie, Halle (Saale)
The lectures and discussions will be held in English language.